Retractable Technologies RVP
- Market cap
- $17.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $33.9M
- −11% on a year ago
- Net margin
- −9.9%
- Free cash flow yield
- −29.4%
Retractable Technologies trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $33.9M over the last twelve months, down 11% on a year earlier with a −10% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.3M−55% | $14.3M+13% | $7.6M−31% | $6M−24% | $10.3M+0% | $9.1M−37% | $8.3M+9% | $10.4M+73% | $10.1M−3% | $9.4M+4% | $7.2M−14% | $7.2M−31% | |
| Cost of revenue | $6M−67% | $12.7M+52% | $5.7M−30% | $6.4M−15% | $10.4M+72% | $11.6M−9% | $8.3M+46% | $10.6M+64% | $8.4M−19% | $11M−5% | $8M−3% | $7M−34% |
| Gross profit | $4.3M−9% | $1.5M−64% | $1.9M−34% | −$419.9K | −$14.8K | −$2.5M | −$1.9K | −$107.1K−75% | $1.7M | −$1.5M−39% | −$838.4K+43773% | $190.9K |
| R&D | $151K+43% | $161.7K+37% | $142.3K+10% | $199.1K+44% | $174.7K+16% | $157.9K−2% | $191.2K+34% | $160K−20% | $199.5K+14% | $124.9K−21% | $170.4K−11% | $187.3K+17% |
| SG&A | $5.1M−4% | $4.2M−65% | $4.7M−13% | $5.1M−2% | $4.9M−3% | $4.6M+10% | $4.5M−6% | $4.9M−5% | $5.1M+4% | $5.1M+12% | $5.2M+15% | $5.1M+6% |
| −$935.9K+36% | −$2.8M−65% | −$3M+9% | −$5.8M+15% | −$5.1M+449% | −$7.2M+160% | −$4.7M+57% | −$5.1M−11% | −$3.7M−29% | −$7.7M+7% | −$6.2M+32% | −$5.1M+0% | |
| Interest expense | $36.1K−10% | $35.1K−22% | $33.5K−23% | $31.8K−15% | $30.5K−16% | $26.7K−24% | $23.5K−30% | $22.3K−30% | $20.6K−33% | $21.6K−19% | $20.4K−13% | $18.7K−16% |
| Pre-tax income | −$5.3M+1298% | −$43.7K−98% | $515K−58% | −$5.9M+22% | −$2M−63% | $3.8M | −$10.2M | −$85.7K−99% | $372.7K | −$2.3M | −$4.2M−59% | $2.8M |
| −$1.2M−79% | $29.2K−98% | $85.6K−63% | $8.3M | −$31.2K−98% | $2K−93% | $285.8K+234% | $1.8K−100% | $1.7K | $2K+2% | $1.8K−99% | $1.8K+1% | |
| Net income | −$4.1M | −$72.9K−98% | $429.4K−57% | −$14.2M+266% | −$1.9M−53% | $3.8M | −$10.5M | −$87.5K−99% | $371K | −$2.3M | −$4.2M−60% | $2.8M |
| −$0.14 | $0.00 | $0.01−67% | −$0.48+269% | −$0.07−50% | $0.12 | −$0.35 | $0.00 | $0.01 | −$0.08 | −$0.14−60% | $0.09 | |
| 29.9M−10% | 29.9M−8% | 29.9M−0% | 29.9M−1% | 29.9M+0% | 29.9M+0% | 29.9M+0% | 29.9M+0% | 29.9M+0% | 29.9M+0% | 29.9M+0% | 29.9M+0% |
EPS, diluted: 15 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY14 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Retractable Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RVPRetractable Technologies | $17.4M | n/m | 8.8× | 0.5× | −11% | −9.9% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on Retractable Technologies
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .